Summary.-Cis-dichlorobis(cyclopentylamine)platinum II (DBCP) belongs to the group of platinum complexes which have recently been reported to have anti-tumour activity. Its cytotoxic activity in CHO cells is not cell-age-dependent, but enhancement of the effect of ionizing radiation is both dose-and cell cycle phase-dependent. In asynchronous cell populations DBCP acts as a dose-modifying factor for ionizing radiation. Doses of DBCP reducing survival of CHO cells to 26% and 4% applied 1 h before irradiation reduce the Do value of radiation dose-survival curves by factors of 1-34 and 1 59 respectively.
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In synchronized CHO populations enhancement by DBCP of the effect of radiation is most pronounced in G1 and in late S while it is reduced in mid-S. Possible mechanisms of DBCP-radiation interaction are discussed. PLATINUM complexes were reported by Rosenberg et al. (1969) to have antibiotic and antitumour activities. Several years later one of the simplest inorganic Pt complexes, cis-dichlorodiammine platinum (II) (cis-DDP) has been reported to be effective in the treatment of some human cancers (e.g. Rossof, Slayton and Perlia, 1972; Wallace and Digby, 1974; Wiltshaw and Carr, 1974) . In 1972, Connors et al. synthesized a series of organic platinum complexes, some of which had significantly higher therapeutic indices than cis-DDP with a plasma-cell tumour in mice.
One of these is cis-dichlorobis(cyclopentylamine)platinum (II), or DBCP. The structure of this coordination complex is shown in Fig. 1 (Connors et al., 1972) . This high value encouraged studies of the effect of DBCP at the cellular level in an in vitro system (Szumiel and Nias, to be published). It was found that (similarly to other Pt complexes studied in other cell culture systems) DBCP inhibits synthesis of DNA in CHO cells. It also interferes with G-S transition and progress through G1 and G2 phases during the first 12 h after treatment and inhibits cell growth by causing lethal as well as non-lethal damage.
The mechanism of cytotoxic activity of Pt complexes is not yet fully understood. It was therefore rather difficult to predict the effect of DBCP pretreatment on the response of CHO cells to ionizing radiation. However, bearing in mind the importance present address: Department of Warsaw, Poland. of drug-radiation interaction for cancer treatment and considering the encouraging report on cis-DDP-x-ray interaction in vivo (Wodinsky et al., 1974) HEPES-buffered (20 mM) Ham's F12 medium (supplemented with 160o calf serum, non-essential amino-acids and 2 mM glutamine) was prepared with 2 different concentrations of Na+ and Cl-ions, using Ham's F12 concentrated (10x) solution. All medium components were supplied by GibcoBiocult Ltd. During the period of these studies the concentration of Na+ and Cl-ions was altered by the suppliers. The original medium (A) contained 106 mM Na+ and 108 mM Cl1: the new medium (B) 119 mM Na+ and 120 mM Cl-. The doubling time of CHO cells in both media was 11-5-12-0 h.
Methods of cell culture were described in detail previously (Nias, 1968) . All treatments were administered after the cells had adhered to the surface of the flasks.
Irradiation.-The 60Co y-ray exposures were carried out using an Orbitron therapy unit, with a dose-rate of 120 rad/min. For later experiments 250 kVp x-irradiations were carried out with a Stabilipan Unit, adapted for cell irradiation. The half-value layer was 1-85 mm Cu, and the dose-rate was 130 rad/min.
Curve fitting.-The dose-survival curves for radiation only were fitted by the least squares method; the curves obtained for combined treatment were drawn by eye from a common extrapolation number.
The (Terasima and Tolmach, 1963) . In order to estimate the degree of synchronization, determinations wAere made of the mitotic index at zero time, and of average cellular multiplicity and labelling index at 1 h intervals. The mitotic index was 950o or higher in all the experimnents reported.
Auatoradiography. This was carried out, and will be described elsewhere (Szumiel and Nias, to be published). Chromosome preparations. The procedure was essentially that of Moorhead et al., (1960) except that hypotonic treatment wsas carried out in 0-7o sodium citrate for 13 min at 37°C. Details of the procedure applied will be given elsewhere (Szumiel and Nias, to be published). About 100 cells w-ere analvsed for each method of treatment.
RESULTS

Combination of DB(R.P and radiation in acsynchronou-s (CHO cell popualations
The response of CHO cells to [)BCP treatment alone was found to be dependent on the composition of the medium used (Szumiel and Nias, to be puiblished). This is illustrated by the data in Table I. Combination of DBCP and radiation was investigated in both A and B medium using either y-or x-rays. Fig. 2 shows 2 examples of DBCP-radiation combination:
(a) DBCP-y-rays in medium A (b) DBCPx-rays in medium B. In these experiments DBCP treatment (for 1 h at 37°C) was followed by irradiation after the cells were maintained for a further 1 h interval at 37°C.
In both examples the survival data, for combined treatment are normalized to survival after DBCP treatment alone. Thus, if there was only an additive effect of both agents the dose-survival curve for combined treatment would be stuperimposed on the curve obtainedl for radiation alone. As may be seen in Fig. 2 there is a clear difference between the 45) 1 390/0 which is on the exponential part of the curve-and it clearly enhances the effect of radiation. However, the same dose in medium B only reduces survival to 55% (on the shoulder of the curve) and there is no enhancement of the effect of radiation. The dose of 33 ,ug/ml is still within the shoulder and again no enhancement is seen. The next higher dose (46 ,ug/ml) is on the exponential part of the curve (survival, 26%) and, when used for pre-treatment, gives a dose-modifying factor of 1-34. An even higher value (1-59) is obtained for 72 ,ug/ml of DBCP in medium B.
The effect of other intervals between DBCP treatment and irradiation was also investigated: the timing used in the 6 experimental protocols is shown diagrammatically in Fig. 4 and the results are tabulated in Table II the radiation dose-survival curves although common extrapolation numbers were found. It was nevertheless possible that a decrease in the sparing effect of split-dose irradiation could be expected in DBCP-pre-treated CHO cells. Indeed, as shown in Fig. 6 , pre-treatment with 26 jtg/ml of DBCP (in medium A) 1 h before the first of two doses of 300 rads of y-rays reduces relative survival (at the maximum level) from 2 to 1 6. Survival level at zero interval (i.e. after 600 rads) is normalized to 1.
Combination of DBCP and radiation in synchronous CHO cell populations In order to throw further light upon the mechanism of interaction of DBCP with radiation, experiments on synchronized CHO cell cultures were carried out. It was found previously (Szumiel and Nias, to be published) that DBCP is not a phase-sensitive drug while x-radiation gives a cell-stage-response with a minimum survival level in G1 and a maximum in mid-S with CHO cells. Fig. 7 shows the stage-response patterns obtained for 450rad of x-rays and 46 ,tg/ml of DBCP separately.
In further experiments synchronized CHO populations in G1, mid-S and late-S phases were subjected to treatment with 46 ,ug/ml of DBCP and, after 1 h, irradiated with 450 rad of x-rays. The design of the experiment is shown in Fig. 8 . The survival data are shown in Table III . The percentage survival that would be expected for additive action is compared with that obtained and the ratio of observed to expected values is taken as a measure of the enhancement of x-ray effect by DBCP. With the ratio of unity, there is no interaction between these agents: the lower the ratio, the greater the enhancement. As may be seen in Table  III , DBCP enhances the effect of x-rays to the greatest extent in the G1 phase and slightly less in late-S, while in mid-S the effect is closer to additive. Table IV. As may be seen, DBCP alone produced a very small number of chromatid aberrations 6 h after the end of treatment. This is understandable since cells were treated with DBCP in the mid-S phase and the mechanism of formation of chromosomal aberrations after drug treatment is of the so-called "delayed" type (Kihlman, 1966) , dependent on DNA synthesis. It involves replication of the damaged (cross-linked) DNA and formation of gaps opposite the damaged sites. These gaps are subsequently filled by de novo synthesis.
DBCP combination with radiation increased the yield of chromatid aberrations more than additively. The increase would be more than additive even if the cells had been treated with DBCP in G1 phase: in a separate experiment on synchronous CHO cells DBCP (46 ,ag/ml, 1 h, 37°C, medium B) was applied in G1 and 13-5 chromatid aberrations per 100 cells were scored in the first mitosis after treatment and 25-2 in the second mitosis (Szumiel and Nias, to be published).
The data in Table IV indicate that DBCP pre-treatment increases the frequency of chromatid aberrations in cells irradiated in late S and G2, the potentiation factor (Kihlman et al., 1974) being 2-2.
With the experimental procedure applied, only part of the asynchronous population could be studied and, therefore, no conclusion can be drawn on the relation of chromosomal aberrations to the lethal effect of combined treatment. However, it is obvious that unrepaired DBCP-induced damage interferes with repair of radiation damage, and the existence of such a direct relation seems possible.
DISCUSSION
There are several rationales for selecting cytotoxic drug combinations, which can also be applied to combinations of radiation and drugs. One of the possibilities is to combine two agents having their maximal lethal effects on cells in different phases of the cell cycle. Good examples of a combination of this kind are actinomycin D and x-rays (Elkind, Sakamoto and Kemper, 1968) and high concentration of methotrexate followed by x-irradiation (Berry, 1968) . Since DBCP is not a phase-specific drug, Another possibility is to combine an agent which slows cell progress through a particular phase of the cell cycle (not by means of a lethal effect) with a second agent that is maximally lethial in that phase (e.g. a non-lethal concentration of methotrexate and radiation, Berry, 1968) . It has been shown (Szumiel and Nias, to be published) that DBCP treatment slows down the rate of DNA synthesis, decreasing at the same time the number of cells entering S phase. Therefore, the mechanism of DBCP-x-ray interaction, observed in the G1 phase (Table III) for DBCP-pre-treated cells. Since in the sparing effect of split-dose irradiation the "cell progress" component is significant, this mechanism could provide an explanation for the results of the DBCP-x-ray split-dose experiment (Fig. 6) .
One can speculate that inhibition of the G1 --+S progression might be due to a rise in the cAMP level, and such a rise has been found after cis-DDP treatment (Tisdale and Phillips, 1 975a). Alkylating agents were reported to have that effect on Walker carcinoma cells (Tisdale and Phillips, 1975b) and the increase of intracellular cAMP was found to be directly related to growth inhibition in 2 lines of Walker ascites carcinoma 256, resistant and sensitive to alkylating agents. It was found (Connors, 1974) and Mitsunobu, 1972) . This kind of explanation could be valid of course only for the type of experiments where DBCP treatment was given prior to radiation. However, the survival data presented suggest that the presence of DBCP inside the cells is not needed to produce an enhancement of the effect of radiation, since DBCP treatment 2 h after irradiation can still decrease the cell survival in a more than additive manner, although the effect is less pronounced than in DBCP pre-irradiation. This means that DBCP may be regarded as analogous to those radiation sensitizers which can be added after irradiation and then interfere with processes leading to cell recovery.
A general principle of the interaction of two agents producing lethal effects by damage of the same target would be that lesions caused by the first agent which are only potentially lethal (using the words "potentially lethal" in a general sense) are converted into lethal lesions by action of the second agent. Thus, the most obvious assumption would be that DBCP interferes with post-irradiation DNA repair. Pt complexes are known to cross-link DNA (Roberts, 1974) and this kind of lesion is repaired most probably by a postreplication type mechanism, whilst the radiation lesions are mostly repaired by rejoining of the single-strand breaks. By creating a steric hindrance (cross-linking) for this repair process DBCP could enhance the number of misrepaired and/or unrepaired radiation lesions even when applied after irradiation. The reverse can also be true: i.e. radiation lesions can interfere with repair of DBCP-damage. In fact, the results of an experiment (Fig. 5) where radiation was applied prior to DBCP can be interpreted as showing a radiation-induced sensitization of CHO cells to DBCP.
It is usually assumed that misrepair leads to non-lethal or lethal mutations, while unrepaired DNA breaks can be visualized at the cytological level as chromosomal aberrations, during mitosis preceding reproductive death. It seems that DBCP disturbs the repair processes, leaving a higher number of DNA breaks unrepaired, since DBCP applied prior to radiation significantly increases the yield of chromatid aberrations in a clearly synergistic manner (Table IV) . Moreover, in the experimental system used, the late-S cells were more readily killed with drug-radiation combination than mid-S cells (Table III) . This is in accord with the data recently published by Burki (1974) , who found that late-replicating chromatin is much more sensitive to ionizing radiation than early-replicating chromatin.
In the light of the present state of knowledge of Pt complexes, DBCP is acting on the same principle as other antitumour platinum compounds, with DNA as the main target molecule. Although there are many steps between in vitro experiments and clinical practice, the results reported here allow one to consider the possibility of obtaining an improved therapeutic ratio by combined treatment with Pt complexes of high antitumour selectivity and low-LET ionizing radiation.
